UA104587C2 - Моноклональное антитело и способ его применения - Google Patents

Моноклональное антитело и способ его применения

Info

Publication number
UA104587C2
UA104587C2 UAA201010915A UAA201010915A UA104587C2 UA 104587 C2 UA104587 C2 UA 104587C2 UA A201010915 A UAA201010915 A UA A201010915A UA A201010915 A UAA201010915 A UA A201010915A UA 104587 C2 UA104587 C2 UA 104587C2
Authority
UA
Ukraine
Prior art keywords
monoclonal antibody
cells
present
antibody
srcr
Prior art date
Application number
UAA201010915A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рамакришнан Меларкоде
Прадип Наир
Сундарадж Дэйвид Раджкумар
Кедарнат Нанджунд Састри
Монализа Чаттерджи
Лаксми Адхикари
Хема Баласубраманиан
Хосе Энрике Монтеро Касимиро
Хосефа Ломбардеро Вальядарес
Роландо Перес Родригес
Original Assignee
Биокон Лимитед
Центро Де Инмунология Молекулар
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41064805&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA104587(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Биокон Лимитед, Центро Де Инмунология Молекулар filed Critical Биокон Лимитед
Publication of UA104587C2 publication Critical patent/UA104587C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к гуманизированному антителу против CD6 изотипа IgGl (Tlh), которое связывается с обогащенным цистеином доменом 1 (D1) фагоцитарного рецептора (SRCR) CD6, присутствующего на поверхности эпителиальных клеток тимуса, моноцитов, активированных Т-клеток и ряда клеток других типов.
UAA201010915A 2008-03-14 2008-09-04 Моноклональное антитело и способ его применения UA104587C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN650CH2008 2008-03-14
PCT/IN2008/000562 WO2009113083A1 (en) 2008-03-14 2008-09-04 A monoclonal antibody and a method thereof

Publications (1)

Publication Number Publication Date
UA104587C2 true UA104587C2 (ru) 2014-02-25

Family

ID=41064805

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201010915A UA104587C2 (ru) 2008-03-14 2008-09-04 Моноклональное антитело и способ его применения

Country Status (26)

Country Link
US (6) US8524233B2 (ru)
EP (2) EP2993186B1 (ru)
JP (3) JP2011513479A (ru)
KR (1) KR20100126811A (ru)
CN (1) CN101970493A (ru)
AR (1) AR072247A1 (ru)
AU (1) AU2008352540B2 (ru)
BR (1) BRPI0822447A2 (ru)
CA (1) CA2716919C (ru)
CL (1) CL2009000618A1 (ru)
CO (1) CO6331445A2 (ru)
DK (1) DK2993186T3 (ru)
EA (1) EA201001467A1 (ru)
ES (1) ES2759075T3 (ru)
HK (1) HK1223941A1 (ru)
IL (1) IL207917A0 (ru)
MX (1) MX2010010085A (ru)
MY (1) MY159517A (ru)
NZ (1) NZ587632A (ru)
PL (1) PL2993186T3 (ru)
PT (1) PT2993186T (ru)
TW (1) TWI485160B (ru)
UA (1) UA104587C2 (ru)
UY (1) UY31710A (ru)
WO (1) WO2009113083A1 (ru)
ZA (1) ZA201005843B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678101B (zh) * 2006-12-26 2012-11-07 分子免疫中心 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物
UA104587C2 (ru) 2008-03-14 2014-02-25 Биокон Лимитед Моноклональное антитело и способ его применения
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA3162352A1 (en) 2010-10-01 2012-04-05 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9428535B2 (en) 2011-10-03 2016-08-30 Moderna Therapeutics, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2791160B1 (en) 2011-12-16 2022-03-02 ModernaTX, Inc. Modified mrna compositions
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
LT2922554T (lt) 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
KR102276745B1 (ko) 2013-07-23 2021-07-14 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
PE20160218A1 (es) * 2013-07-23 2016-05-09 Biocon Ltd Metodos para controlar los niveles de fucosilacion en proteinas
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
CA2926218A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CN104497141B (zh) * 2014-12-31 2017-10-10 百泰生物药业有限公司 抗人cd6分子的治疗性抗体
RU2726254C2 (ru) * 2015-02-12 2020-07-10 Юниверсити Оф Саутерн Калифорния Блокаторы рецептора гормона роста при предупреждении заболеваний и лечении
CN109311992B (zh) 2016-06-15 2022-10-18 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
EP3528846A4 (en) * 2016-10-18 2020-06-03 Biocon Limited USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
KR102514528B1 (ko) * 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
CN108178797B (zh) * 2017-12-29 2020-12-01 西南大学 一种抗家蚕BmSRC多克隆抗血清、制备方法及应用
SG11202008149RA (en) 2018-02-27 2020-09-29 Equillium Inc Anti cd6 antibodies for treating severe asthma
AU2019295855A1 (en) * 2018-06-29 2021-01-28 City Of Hope CD6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
MX2021010283A (es) 2019-02-26 2021-09-30 Equillium Inc Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
IL311287A (en) 2021-09-08 2024-05-01 Ct Inmunologia Molecular Use of anti-CD6 monoclonal antibodies in the prevention of damage to cells and organs as a result of a hyper-inflammatory reaction

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
AU703694B2 (en) 1993-11-02 1999-04-01 Bristol-Myers Squibb Company CD6 ligand
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
BR9609743A (pt) 1995-07-27 1999-03-02 Genentech Inc Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
ATE207889T1 (de) 1996-03-20 2001-11-15 Aventis Pharma Sa Trizyclische verbindungen mit wirkung auf integrine, besonders auf das alphavbeta3-integrin,verfahren zur ihrer herstellung und zwischenprodukte des verfahrens, ihre verwendung als arzneimittel und sie enthaltende pharmazeutische zusammensetzungen
JP2001523956A (ja) * 1997-03-03 2001-11-27 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｃｄ６に対するモノクローナル抗体
WO1998047531A2 (en) * 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
AU2001250814B2 (en) 2000-03-16 2007-02-15 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
JP2003534022A (ja) 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
AU2003265361A1 (en) 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
LT2335725T (lt) 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
EP2168986A3 (en) * 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
EA010350B1 (ru) 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
JP2008528638A (ja) 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
AU2007331712A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
ES2785043T3 (es) 2006-12-26 2020-10-05 Ct Inmunologia Molecular Composición farmacéutica, que comprende un anticuerpo monoclonal anti-cd6 usado en el diagnóstico y tratamiento de la artritis reumatoide
CN101678101B (zh) 2006-12-26 2012-11-07 分子免疫中心 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
CN101675076B (zh) 2007-02-28 2013-09-18 默沙东公司 工程化的抗il-23r抗体
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
UA104587C2 (ru) 2008-03-14 2014-02-25 Биокон Лимитед Моноклональное антитело и способ его применения
US9403904B2 (en) 2008-11-07 2016-08-02 Fabrus, Inc. Anti-DLL4 antibodies and uses thereof
DK3721904T3 (da) 2009-11-20 2021-11-15 Biocon Ltd Formuleringer af t1h-antistof
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
PE20160218A1 (es) 2013-07-23 2016-05-09 Biocon Ltd Metodos para controlar los niveles de fucosilacion en proteinas
KR102276745B1 (ko) 2013-07-23 2021-07-14 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
CN109311992B (zh) 2016-06-15 2022-10-18 克利夫兰临床基金会 用于治疗t细胞介导疾病的新型抗cd6抗体
WO2018024896A1 (en) 2016-08-05 2018-02-08 INSERM (Institut National de la Santé et de la Recherche Médicale) EX VIVO GENERATION OF γδ FOXP3+ REGULATORY T CELLS AND THERAPEUTIC USES THEREOF
EP3528846A4 (en) 2016-10-18 2020-06-03 Biocon Limited USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
SG11202008149RA (en) 2018-02-27 2020-09-29 Equillium Inc Anti cd6 antibodies for treating severe asthma
MX2021010283A (es) 2019-02-26 2021-09-30 Equillium Inc Composiciones de anticuerpo anti-cd6 y metodos para tratar lupus.
US20230151107A1 (en) 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
MX2023006595A (es) 2020-12-04 2023-08-11 Equillium Inc Metodos para dirigir selectivamente celulas con cd6alto y para disminuir la actividad de linfocitos tef.

Also Published As

Publication number Publication date
CN101970493A (zh) 2011-02-09
DK2993186T3 (da) 2019-11-25
BRPI0822447A2 (pt) 2015-06-16
HK1223941A1 (zh) 2017-08-11
EA201001467A1 (ru) 2011-06-30
US20110002939A1 (en) 2011-01-06
MX2010010085A (es) 2011-03-29
ES2759075T3 (es) 2020-05-07
AU2008352540B2 (en) 2012-06-28
US20180258179A1 (en) 2018-09-13
US9670285B2 (en) 2017-06-06
PL2993186T3 (pl) 2020-02-28
JP2014065711A (ja) 2014-04-17
PT2993186T (pt) 2019-11-29
US20160168256A1 (en) 2016-06-16
CO6331445A2 (es) 2011-10-20
US9217037B2 (en) 2015-12-22
US10669346B2 (en) 2020-06-02
MY159517A (en) 2017-01-13
KR20100126811A (ko) 2010-12-02
AU2008352540A1 (en) 2009-09-17
US20210122829A1 (en) 2021-04-29
NZ587632A (en) 2012-06-29
EP2265644A1 (en) 2010-12-29
ZA201005843B (en) 2011-04-28
CL2009000618A1 (es) 2011-05-27
US10000573B2 (en) 2018-06-19
JP2014159425A (ja) 2014-09-04
AR072247A1 (es) 2010-08-18
TW201000125A (en) 2010-01-01
US20140031529A1 (en) 2014-01-30
EP2993186B1 (en) 2019-09-04
JP2011513479A (ja) 2011-04-28
EP2993186A1 (en) 2016-03-09
TWI485160B (zh) 2015-05-21
UY31710A (es) 2009-11-10
CA2716919A1 (en) 2009-09-17
CA2716919C (en) 2015-01-20
JP5856209B2 (ja) 2016-02-09
WO2009113083A1 (en) 2009-09-17
US8524233B2 (en) 2013-09-03
US20170281808A1 (en) 2017-10-05
US11981743B2 (en) 2024-05-14
EP2265644A4 (en) 2011-04-27
IL207917A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
UA104587C2 (ru) Моноклональное антитело и способ его применения
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
RS54056B1 (en) ANTI-CD38 HUMAN ANTIBODIES AND THEIR USES
CU24663B1 (es) Dominio de unión a antígeno anti-trbc1, receptor de antígeno quimérico, anticuerpo y acoplador biespecífico de células t que comprenden el mismo
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
NZ601617A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
RS53750B1 (en) NOTCH1 RECEPTOR BINDING AGENTS AND APPLICATION PROCEDURES
RS53120B (en) ANTAGONISTIC HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO THE HUMAN LIGHT
GEP20125612B (en) Prlr-specific antibody and usage thereof
RS54624B1 (en) MONOCLONIC ANTIBODIES AGAINST GLIPICAN-3
UA101487C2 (en) Humanized b-ly1 antibody formulation
NZ600262A (en) Anti-her3 antibodies and uses thereof
NZ623319A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
MX2009003774A (es) Anticuerpos para linfotoxina-alfa.
PE20110801A1 (es) Anticuerpos con reactividad cruzada y biespecificos anti-il-17a/f
EA200802168A1 (ru) Гуманизированное антитело к с-kit
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
RS53263B (en) CD19 OPTIMIZED ANTIBODY
WO2008140653A3 (en) Humaneered anti-factor b antibody
UA97946C2 (ru) Моноклональное антитело, специфически связывающееся с внеклеточным доменом ilt7 человека
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
IL197928A (en) A monoclonal antibody munched on steap-1, its immunoconjugates its uses
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR